Objectives: To study the isolates with acquired resistance to bedaquiline and linezolid that were obtained from patients enrolled in a clinical study of a novel therapy regimen for drug-resistant TB in Moscow, Russia.
Introduction
MDR TB with additional resistance to fluoroquinolones or secondline injection drugs and XDR TB are an increasing public health threat, demanding the development of novel drugs and regimens for successful treatment.
Bedaquiline is a novel anti-TB drug 1 and the first drug acting specifically on mycobacterial ATP synthase. 2 Both in vitro-selected and clinical isolates resistant to bedaquiline have been reported. 1, [3] [4] [5] [6] [7] Substitutions in the c subunit of ATP synthase prevent interaction of the drug with its target, 4, 8 whereas mutations in the repressor gene mmpR (Rv0678) locus lead to increased expression of the efflux genes mmpL5 and mmpS5, providing export of bedaquiline, clofazimine 9 and econazole. 10 Recently, the association of loss-of-function mutations in the pepQ locus with resistance to bedaquiline and clofazimine was described. 11 Linezolid, which was approved by the FDA in 2000 for the treatment of various Gram-positive infections, 12 has demonstrated bacteriostatic activity against Mycobacterium tuberculosis in vitro as well as in animal models. 12, 13 Tolerability and efficacy studies have justified the use of linezolid for the treatment of drugresistant TB.
14 Linezolid binds the ribosome at the peptidyl-transferase centre, 15 and resistant strains from in vitro and clinical studies contain mutations in the 23S rRNA and L3 ribosomal protein genes. 12, [16] [17] [18] Bedaquiline is a recently approved drug for the treatment of TB and its safety and efficacy were tested in several clinical studies in the Russian Federation. 19, 20 At the Moscow Research and Clinical Centre for Tuberculosis Control, the novel medication scheme in most cases also includes linezolid, which has been used in Russia since 2010. 21, 22 This ongoing trial is a prospective, non-randomized, open-label study of the efficacy and safety of a bedaquilinecontaining regimen for the treatment of drug-resistant TB, with some results having been published. 19 Importantly, patients with XDR forms of TB and with comorbidities such as alcohol or drug V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. addiction were not excluded from the study. In this report, we describe the phenotypic and genetic characteristics of isolates with acquired resistance to bedaquiline and linezolid obtained from patients enrolled in this study.
Methods

Study design
This was a prospective, non-randomized, open-label study because of the use of drugs not recommended for TB treatment or longer periods of administration. According to the laws of the Russian Federation, in this case, the prescription was made by medical consultation, leading to the impossibility of undertaking a blind and randomized clinical study. In total, samples from 27 patients were analysed in this study. Seventy-eight percent of these patients had been administered the core drug combination of bedaquiline, linezolid, fluoroquinolones and cycloserine/terizidone. 19 According to the Ethics Committee of the Moscow Research and Clinical Centre for Tuberculosis Control, this research did not require ethics approval. All samples used in this study were coded and lacked personal information about the patients, especially names and addresses, to maintain their anonymity.
Respiratory samples were decontaminated using the BBL MycoPrep reagent (Becton Dickinson, Cockeysville, MD, USA), containing N-acetyl-Lcysteine and NaOH, according to the manufacturer's instructions. Part of the processed sample was used for automatic Bactec MGIT 960 culture.
Drug susceptibility testing
Drug susceptibility testing for streptomycin, pyrazinamide, rifampicin, isoniazid, ethambutol, ofloxacin, moxifloxacin, kanamycin, amikacin, paraaminosalicylic acid and ethionamide was performed using Bactec MGIT 960 as described previously. 23, 24 Susceptibility testing for cycloserine was performed on Lowenstein-Jensen medium using the critical concentration of 30 mg/L. The MIC of bedaquiline (Pharmstandard-UfaVita JSC, Ufa, Russia; Janssen Pharmaceutica, Beerse, Belgium) was determined using Middlebrook 7H11 agar plates supplemented with the drug at the following concentrations: 0.03, 0.06, 0.12, 0.25, 0.50 and 1.00 mg/L. The selection criterion for strains was an elevated MIC of bedaquiline compared with the MIC for the susceptible isolates, WT strain H37Rv and, also, previously published data equal to 0.03 mg/L. 25 Linezolid (Sigma-Aldrich Co., St Louis, MO, USA) resistance was determined using MGIT 960 (critical concentration of 1 mg/L). 26 
DNA isolation and sequencing
DNA from samples and isolates was isolated using an automated DNA extraction workstation based on the Freedom EVO V R Clinical (Tecan Group Ltd, M€ annedorf, Germany). Fragments of the mmpR (Rv0678), atpE, atpC, pepQ, Rv1979c, rrl, rplC and rplD genomic loci were amplified with their corresponding pairs of primers (Table S1 , available as Supplementary data at JAC Online). The 30 lL reaction volume contained 3 U of Qiagen HotStarTaq DNA polymerase, 1 % Qiagen PCR buffer, 3 mM MgCl 2 (all three were from Qiagen GmbH, Hilde, Germany), 200 lM of each dNTP (Evrogen LLC, Moscow, Russia), 1 lM of each primer and 1 lL of the DNA sample. The PCR cycling conditions were as follows: initial denaturation at 95 C for 4 min; 40-50 cycles of denaturation at 95 C for 40 s, annealing at primer-specific temperature (Table S1) for 30 s, extension at 72 C for 30 s; and final extension at 72 C for 5 min. Fragments were purified from agarose gels using the MinElute gel extraction kit (Qiagen GmbH, Hilde, Germany) and subjected to dideoxy sequencing using ABI Prism BigDye Terminator version 3.1 (Applied Biosystems, Foster City, CA, USA).
Results
Selection of clinical isolates
Isolates from patients receiving bedaquiline and linezolid in their medication scheme were analysed using a combination of phenotypic and genetic methods. As described previously, a number of experiments with H37Rv and pan-susceptible isolates from primary TB cases confirmed that the MIC value for bedaquilinesusceptible strains was 0.03 mg/L. 25 Strains with reduced bedaquiline susceptibility possessing MIC values 0.06 mg/L were selected for detailed genetic analysis. In total, elevated MICs of bedaquiline for at least one isolate were detected in 24 patients (out of 116 analysed; data not shown).
For 7 of the 24 cases, MICs of 0.06-0.25 mg/L were identified in the initial cultures preceding treatment ( Table 1) . Two of seven cases rapidly became culture-negative after the initiation of treatment and no post-treatment cultures were obtained. In four of five cases, the bedaquiline MIC elevated during treatment and in one case it did not change.
In 10 cases, the bedaquiline MIC increased from 0.03 mg/L to different levels up to 0.25 mg/L and for 7 patients no initial cultures were available. Therefore, initial and post-treatment isolates from bedaquiline-treated cases were available from 15 patients.
The linezolid-resistant isolates were obtained from 10 patients. Three of the patients were confirmed cases of acquisition of resistance during treatment (patients Bc, Bg and Ci in Table 2 ) and the bedaquiline MIC was also elevated in these cases. The corresponding initial isolates for four additional isolates (patients Ab, Bn, Di and Ee) were not available; however, in the case of patient Di the first isolate obtained during the treatment course was susceptible to linezolid and bedaquiline, and subsequent isolates showed resistance to both drugs (Table S2 ). Three patients with resistant isolates (Cy, Ae and Fa) had a previous history of treatment with linezolid. In addition, no initial isolates were available for them.
In 11 patients receiving linezolid, resistance did not develop. Furthermore, five patients were not treated with linezolid during therapy, primarily due to toxic side effects, and one patient (Bd) became rapidly negative after the start of treatment.
Six patients developed resistance to both linezolid and bedaquiline during treatment (patients Bc, Bg, Ci, Cy, Bn and Di in Table S2 ) and one patient (Ae) with resistance to linezolid did not receive bedaquiline. Therefore, three patients with isolates resistant to linezolid and susceptible to bedaquiline were added to the study in addition to the 24 cases mentioned above. As a result, 85 culture isolates from 27 patients were selected for further analyses. A summary of the drug susceptibility testing and genetic analysis of all isolates described in this study is provided in Table S2 .
Identification of mutations associated with elevated MIC of bedaquiline
Sixty-five isolates from 24 patients had bedaquiline MICs 0.06 mg/L. Five genomic loci were sequenced to identify mutations associated with resistance to bedaquiline: mmpR (Rv0678), atpE, atpC, pepQ and Rv1979c. Substitutions were identified in 52 of the 65 isolates (Figure 1) . In 26 isolates, mixed sequencing chromatogram data were observed and they were manually examined.
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In strains with elevated MICs of bedaquiline, most mutations were found in the mmpR gene (in 51 of 65 strains). Due to the nature of the resistance mechanism in which inactivation of the repressor MmpR increases efflux of bedaquiline, the mutations were dispersed nearly randomly along the open reading frame. Both frameshift mutations and amino acid substitutions were identified (Table 1) . Mutational hotspots at nucleotides 139 and 198 were identified; isolates from three and five patients, Bedaquiline and linezolid resistance in clinical isolates JAC respectively, bore exactly the same mutation at these positions (Table S3 ). Six isolates from two patients bore amino acid substitutions in AtpE: D28N and A63V. In patient Af the AtpE(A63V) substitution emerged during treatment in addition to the existing MmpR(L142R) and an intermediate mixed state of WT and mutated sequences was registered (Table S2) .
In seven patients, isolates with elevated MICs of bedaquiline were detected before treatment with bedaquiline: three of them possessed high MICs, of 0.12-0.25 mg/L, and four had intermediate MICs, of 0.06 mg/L, which was also higher than that of the susceptible isolates from primary TB cases. In three cases with high MIC and one case with intermediate MIC, substitutions in MmpR were identified (Table 1) . No mutations were found in the atpC, pepQ or Rv1979c genes.
Identification of mutations associated with resistance to linezolid
The mutation t460c in the rplC gene, leading to C154R substitution in ribosomal protein L3, 18 was found in 9 of 10 isolates resistant to linezolid (Table 2) . Two sequential isolates from one patient contained ambiguous sequencing chromatograms at two positions in rplC: a mix of c and a instead of t at 460 and a mix of g and t at nucleotide t462 ( Figure S1 ). Without an analysis of individual clones' sequences, this situation leads to two possible variants of substitution mixes of RplC: C154R ! C154R and C154R ! C154S.
Three types of mutations were found in the 23S rRNA gene sequence in linezolid-resistant isolates: c1921t, g2294a and g2814t. Position 1921 belongs to domain IV of 23S rRNA, far from the peptidyl-transferase centre, and thus is unlikely to be associated with linezolid resistance. The second, g2294a, was found in a mixed population together with WT sequence. In Escherichia coli numbering, it corresponds to nucleotide 2056, which is basepaired to c at nucleotide 2612. A substitution with a at this position was found in Mycobacterium smegmatis resistant to linezolid. 27 The third mutation, g2814t (2576 in E. coli numbering), was previously found in various linezolid-resistant organisms, 17 and this isolate had no mutations in rplC. No mutations were identified in the rplD gene. In contrast to bedaquiline susceptibility genetics, sequence mixes in the rrl and rplC genes were less diverse and no transition state isolates were identified. Mixes were found in three isolates from two patients (Table S2 ).
Discussion
Treatment of MDR and XDR TB is a complex task due to the small number of effective drugs and the high risk of adverse effects. There is a potential risk of acquisition of additional drug resistance from inappropriate treatment and pulmonary complications such as extensive lesions. 28 Following a clinical study of novel regimens, including the recently approved drugs bedaquiline and linezolid, held in the Moscow Research and Clinical Centre for Tuberculosis Control, we investigated resistance to these two drugs and analysed the genetic determinants of this resistance in clinical isolates obtained from patients.
Comparison of bedaquiline MIC values and the presence of mutations associated with bedaquiline resistance showed ambiguous results at two serial dilutions: most strains with MICs of 0.12 mg/L had substitutions, although some did not, and the opposite situation was observed for MICs of 0.06 mg/L. In all isolates with higher MICs, various substitutions were identified, and all strains with MICs of 0.03 mg/L had WT sequences of the studied genes. Although we analysed the sequences of five known genes, we propose the existence of some other mechanism of bedaquiline resistance, also confirmed by the presence of identical mutations in isolates with different MICs.
A large variety of frameshift mutations and amino acid substitutions were identified in the mmpR repressor sequence of isolates with elevated MICs of bedaquiline. Although several hotspots in mmpR were identified in this study, confirming previous observations of in vitro-selected clofazimine-resistant strains, 29 the mutations are mostly distributed throughout the whole gene, consistent with the resistance mechanism. 9 This complicates the development of molecular diagnostic methods other than direct sequencing of the entire ORF, the same situation as for the pncA gene in pyrazinamide resistance 30 and the tlyA gene in capreomycin resistance. 31 In addition it should be noted that, in contrast to inactivating frameshift mutations, amino acid substitutions do not necessarily alter the functional properties of the repressor.
Previously only mutations in mmpR had been identified in clinical isolates, 6, 7, 32, 33 whereas mutants selected in vitro also bear substitutions in subunit c of ATP synthase. 1, 5 We identified two new types of substitutions associated with increased MICs of bedaquiline: D28N and A63V in AtpE. To our knowledge, these exact substitutions have not been described previously: in a number of studies, D28 was replaced with P, V, A or G, and A63 was replaced with P. 1, [3] [4] [5] No fitness cost for AtpE mutations has been detected in vitro 3 as estimated by cfu calculations; however, the lower frequency of such mutations in clinical isolates potentially indicates that they have an additional cost in vivo.
In seven patients, isolates with elevated MICs of bedaquiline were detected before treatment, three of which possessed high MICs. Four strains had substitutions in MmpR, similar to the findings of Torrea et al. 33 Upon analysis of the GMTV database containing genomic data on 2000 Russian isolates, only 1 strain with a frameshift mutation and 13 isolates with non-synonymous amino acid Zimenkov et al.
substitutions in MmpR could be found using a quality threshold recommended by the authors. 34 This is a much lower frequency of mutations compared with our findings, although the proportion of MDR and XDR strains in this database is not known. Variability in the bedaquiline MIC for isolates not previously exposed to the drug could be associated with changes in the regulatory network of bedaquiline tolerance 35 affected by a prior history of treatment or by the presence of former selective pressures from unknown factors. In our study, all such patients had had the chronic form of TB for many years and they had no history of previous bedaquiline or clofazimine treatment. However, most of them (five of seven, excluding patients Ae and Bc) were previously treated with azole medications (fluconazole, itraconazole, voriconazole etc.) for pulmonary fungal coinfections. Previously, it was shown that mutations in the MmpS5-MmpL5 efflux protein repressor MmpR resulted in resistance to azoles, including the antifungal econazole. 10 Nevertheless, this hypothesis needs further experimentation for validation.
No mutations in pepQ, which was recently reported in strains with low-level resistance to bedaquiline, 11 were found in the studied isolates. Additionally, substitutions in Rv1979c and pepQ have previously been associated with clofazimine resistance, 29 and no mutations in Rv1979c have been detected either; thus, the genetic mechanisms of elevated MIC for the 12 strains from the seven patients are yet to be revealed.
Among the linezolid-resistant isolates, mutations t460c in the rplC gene were the most frequent, which is in line with previous studies. 18 A double mutation at positions 460 and 462 leading to the same amino acid substitution, which was found in one case, had not been previously described. Isolates from two patients bore mutations in the 23S rRNA gene associated with linezolid resistance-the well-known g2814t and g2294a, which had not been previously identified.
Mixed subpopulations of pathogens were found in 40% of cases, being identified by Sanger sequencing of DNA purified from isolated culture. Various types of mixes related to heteroresistance were found: a mix of WT and mutated DNA, as well as mixes of DNAs with different mutations, reflecting the complex nature of pathogen evolution in vivo. A limitation of the findings could be the use of MGIT cultures for analysis, which alters the population diversity, and a significant percentage of mixed subpopulations could have been lost during cultivation. 36 Mixed TB infections and subpopulations that evolve from one progenitor are frequently detected in clinical samples, 37 affecting susceptibility testing both by phenotypic methods 38 and by molecular methods. 39 Current molecular approaches for the detection of mixed strains have limited sensitivity in the case of unknown mutations and the most informative method is probably the next-generation sequencing approach with extremely highdepth reading performed directly on sputum samples. 40 The Sanger sequencing method used in our study has an 10%-15% false negative rate for SNP detection; 41 however, this rate is lower for the detection of indels compared with SNPs due to the continuous nature of secondary peaks on the chromatogram after a site with a nucleotide insertion or deletion.
Our study supports previous findings of high within-host population diversity identified in follow-up isolates from the same patient receiving ongoing medical treatment. We identified preexisting bedaquiline resistance in XDR patients and patients with acquired resistance to bedaquiline, linezolid or both drugs simultaneously under the selective pressure of therapy. This strongly points to the need for susceptibility testing for a maximal number of drugs before drug prescription and continued monitoring during treatment using all available methods.
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